Valerio Therapeutics (FR:ALVIO)
:ALVIO
Want to see FR:ALVIO full AI Analyst Report?
Total Valuation
Valerio Therapeutics has a market cap or net worth of €84.76M. The enterprise value is €66.00M.
Market Cap€84.76M
Enterprise Value€66.00M
Share Statistics
Valerio Therapeutics has 499,448,300 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding499,448,300
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Valerio Therapeutics’s return on equity (ROE) is -2.36 and return on invested capital (ROIC) is -5.50%.
Return on Equity (ROE)-2.36
Return on Assets (ROA)-0.32
Return on Invested Capital (ROIC)-5.50%
Return on Capital Employed (ROCE)-0.06
Revenue Per Employee67.71K
Profits Per Employee-128.89K
Employee Count38
Asset Turnover0.17
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Valerio Therapeutics is ―. Valerio Therapeutics’s PEG ratio is 0.05.
PE Ratio―
PS Ratio8.28
PB Ratio10.27
Price to Fair Value10.27
Price to FCF40.89
Price to Operating Cash Flow14.27
PEG Ratio0.05
Income Statement
In the last 12 months, Valerio Therapeutics had revenue of 2.57M and earned -4.90M in profits. Earnings per share was -0.03.
Revenue2.57M
Gross Profit1.73M
Operating Income-550.00K
Pretax Income-4.64M
Net Income-4.90M
EBITDA542.00K
Earnings Per Share (EPS)-0.03
Cash Flow
In the last 12 months, operating cash flow was 1.84M and capital expenditures -1.32M, giving a free cash flow of 521.00K billion.
Operating Cash Flow1.84M
Free Cash Flow521.00K
Free Cash Flow per Share<0.01
Dividends & Yields
Valerio Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-0.91
52-Week Price Change174.19%
50-Day Moving Average0.14
200-Day Moving Average0.11
Relative Strength Index (RSI)62.44
Average Volume (3m)1.36M
Important Dates
Valerio Therapeutics upcoming earnings date is Oct 29, 2025, During Market Hours (Confirmed).
Last Earnings DateJul 9, 2025
Next Earnings DateOct 29, 2025
Ex-Dividend Date―
Financial Position
Valerio Therapeutics as a current ratio of 0.76, with Debt / Equity ratio of 366.60%
Current Ratio0.76
Quick Ratio0.76
Debt to Market Cap0.34
Net Debt to EBITDA12.09
Interest Coverage Ratio-1.96
Taxes
In the past 12 months, Valerio Therapeutics has paid 261.00K in taxes.
Income Tax261.00K
Effective Tax Rate-0.06
Enterprise Valuation
Valerio Therapeutics EV to EBITDA ratio is 51.40, with an EV/FCF ratio of 53.47.
EV to Sales10.83
EV to EBITDA51.40
EV to Free Cash Flow53.47
EV to Operating Cash Flow15.15
Balance Sheet
Valerio Therapeutics has €1.05M in cash and marketable securities with €7.61M in debt, giving a net cash position of -€6.55M billion.
Cash & Marketable Securities€1.05M
Total Debt€7.61M
Net Cash-€6.55M
Net Cash Per Share-€0.01
Tangible Book Value Per Share-€0.04
Margins
Gross margin is 67.08%, with operating margin of -21.38%, and net profit margin of -190.36%.
Gross Margin67.08%
Operating Margin-21.38%
Pretax Margin-180.22%
Net Profit Margin-190.36%
EBITDA Margin21.06%
EBIT Margin-169.30%
Analyst Forecast
The average price target for Valerio Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast-3.12%
EPS Growth Forecast30.49%